![Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated)](/content/dam/biopharm/rebinyn/global/rebinyn_logo.png){kind=logo}
A single dose of Rebinyn® 40 IU/kg was shown to elevate factor levels above their normal levels in pediatric patients.d Take a look at the numbers:
TAKE CONTROL WITH HIGH FACTOR LEVELS
Rebinyn® is proven to achieve and maintain higher factor levels.a
aBased upon a phase 1 study comparing 25, 50, and 100 IU/kg doses of Rebinyn® to a 50 IU/kg dose of standard half-life rFIX in 7 adults and a 50 IU/kg dose of plasma-derived FIX in 8 adults. For Rebinyn®, estimated average FIX activity is adjusted to a dose of 50 IU/kg.
bIn two phase 3 studies, factor levels were evaluated for 1 week after the first dose of Rebinyn® 40 IU/kg. The average levels after 7 days were 16.8% in 6 adults, 14.6% in 3 adolescents, 10.9% in 13 children ages 7 to 12 years, and 8.4% in 12 children up to age 6 years.
cBased upon a 2.34% increase in factor levels per IU/kg infused in adults.
Half-life is the time it takes for the level of factor in the blood to fall by half (50%).
HIGH FACTOR ACTIVITY IN CHILDREN AND ADOLESCENTS
dBased on pharmacokinetic assessment of a single dose of Rebinyn® 40 IU/kg after 7 days in 3 adolescents (mean FIX activity 14.6%), 13 children aged 7 to 12 (mean FIX activity 10.9%), and 12 children aged 0-6 (mean FIX activity 8.4%) upon enrollment in the phase 3 trials using 1-stage assay and product-specific standard. All values are geometric mean.
eBased upon a 1.51% increase in factor levels per IU/kg infused in children aged ≤6.
fBased upon a 1.59% increase in factor levels per IU/kg infused in children aged 7-12.
gBased upon a 1.96% increase in factor levels per IU/kg infused in adolescents aged 13-17.
INTERESTED IN TRYING REBINYN®?
To learn more about our free trial prescription program, please call 1-844-668-6732 to speak with a NovoSecure™ Specialist.h
hPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.
DESIGNED WITH SAFETY IN MIND
In clinical studies, Rebinyn® was shown to be safe and effective.
CONSIDERING A SWITCH?
See how Factor IX therapies compare on features that matter to you—from storage conditions to infusion time.
